Knockdown of the histone di-methyltransferase G9a in nucleus accumbens shell decreases cocaine self-administration, stress-induced reinstatement, and anxiety.
Animals
Anxiety
/ metabolism
Behavior, Addictive
/ physiopathology
Behavior, Animal
/ physiology
Cocaine
/ pharmacology
Electric Stimulation
Extinction, Psychological
/ drug effects
Gene Knockdown Techniques
Histone-Lysine N-Methyltransferase
/ genetics
Male
Nucleus Accumbens
/ metabolism
Rats
Recurrence
Reinforcement Schedule
Self Administration
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
16
04
2018
accepted:
16
12
2018
revised:
06
12
2018
pubmed:
28
12
2018
medline:
1
4
2020
entrez:
28
12
2018
Statut:
ppublish
Résumé
Comorbid neuropsychiatric disorders such as addiction and anxiety could involve common underlying mechanisms. One potential mechanism involves epigenetic regulation of histone 3 dimethylation at lysine 9 residues (H3K9me2) by the histone dimethyltransferase G9a. Here we provide evidence that local AAV-RNAi-mediated knockdown of G9a expression in nucleus accumbens shell (NAcSh) of male rats reduces both addictive-related and anxiety-related behaviors. Specifically, G9a knockdown reduces sensitivity to low dose cocaine reinforcement when cocaine is freely available (fixed ratio schedule). Similarly, G9a knockdown reduces motivation for cocaine under higher effort demands (progressive ratio schedule). Following several weeks of forced abstinence, G9a knockdown attenuates extinction responding and reinstatement triggered by either cocaine-priming injections or footshock stress. This decrease in addictive behavior is associated with a long-term reduction in anxiety-like behavior as measured by the elevated plus maze (EPM). G9a knockdown also reduces basal anxiety-like behavior in EPM and marble burying tests in drug-naïve rats. These results complement our previous work showing that increased G9a expression in NAcSh enhances addictive-related and anxiety-related behaviors, indicating that G9a bi-directionally controls these responses. These results also suggest that regulation of G9a-influenced gene expression could be a common epigenetic mechanism for co-morbid anxiety and psychostimulant addiction.
Identifiants
pubmed: 30587852
doi: 10.1038/s41386-018-0305-4
pii: 10.1038/s41386-018-0305-4
pmc: PMC6785019
doi:
Substances chimiques
Ehmt2 protein, rat
EC 2.1.1.43
Histone-Lysine N-Methyltransferase
EC 2.1.1.43
Cocaine
I5Y540LHVR
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1370-1376Subventions
Organisme : NIDA NIH HHS
ID : T32 DA007290
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA007359
Pays : United States
Organisme : NIDA NIH HHS
ID : R37 DA007359
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA014133
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA032708
Pays : United States
Organisme : NIDA NIH HHS
ID : P01 DA008227
Pays : United States
Organisme : NIMH NIH HHS
ID : P50 MH096890
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA027664
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Neuron. 2009 Dec 10;64(5):678-91
pubmed: 20005824
Behav Brain Res. 2014 Aug 1;269:28-36
pubmed: 24739359
Naunyn Schmiedebergs Arch Pharmacol. 1984 Aug;327(1):1-5
pubmed: 6149466
Eur J Neurosci. 2019 Aug;50(3):2477-2491
pubmed: 30251397
Scand J Psychol. 1987;28(3):242-9
pubmed: 3441771
J Neurosci. 2012 Nov 28;32(48):17454-64
pubmed: 23197736
Am J Psychiatry. 2012 Sep;169(9):926-36
pubmed: 22952072
Eval Rev. 2007 Dec;31(6):585-612
pubmed: 17986709
Curr Psychiatry Rep. 2015 Feb;17(2):4
pubmed: 25617040
JAMA Psychiatry. 2013 Dec;70(12):1338-46
pubmed: 24132249
Addict Biol. 2012 Mar;17(2):378-91
pubmed: 21955224
Behav Pharmacol. 2007 Feb;18(1):53-60
pubmed: 17218797
Psychopharmacology (Berl). 2012 Jul;222(1):89-97
pubmed: 22245944
Biol Psychiatry. 2005 Jul 15;58(2):158-64
pubmed: 16038686
Epigenetics. 2011 Sep 1;6(9):1095-104
pubmed: 21814037
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):9469-9474
pubmed: 28808012
J Neurosci. 2018 Jan 24;38(4):803-813
pubmed: 29217682
Addict Biol. 2011 Jul;16(3):450-7
pubmed: 21309958
J Neurosci. 2016 Aug 10;36(32):8441-52
pubmed: 27511015
Neurosci Biobehav Rev. 2004 Jan;27(8):721-8
pubmed: 15019422
Neuropsychopharmacology. 2017 Apr;42(5):1113-1125
pubmed: 28042872
Science. 2010 Jan 8;327(5962):213-6
pubmed: 20056891
Acta Pharmacol Sin. 2018 May;39(5):866-874
pubmed: 29417943
Psychiatr Danub. 2015 Sep;27 Suppl 1:S452-5
pubmed: 26417814
Pharmacol Biochem Behav. 2004 Oct;79(2):317-24
pubmed: 15501308
Science. 1998 Dec 18;282(5397):2272-5
pubmed: 9856954
Nat Neurosci. 2007 Aug;10(8):1029-37
pubmed: 17618281
Learn Mem. 2005 May-Jun;12(3):296-301
pubmed: 15930508
Neuron. 2011 Aug 25;71(4):656-70
pubmed: 21867882
Sci Rep. 2015 Nov 05;5:16283
pubmed: 26538334
Eur J Neurosci. 2007 Apr;25(7):2201-13
pubmed: 17439498
Prim Care Companion J Clin Psychiatry. 1999 Aug;1(4):109-113
pubmed: 15014683
Neuropsychopharmacology. 2007 Feb;32(2):354-66
pubmed: 16541082
Nat Neurosci. 2014 Apr;17(4):533-9
pubmed: 24584053
Curr Protoc Neurosci. 2015 Oct 01;73:4.37.1-4.37.31
pubmed: 26426386
Brain Res. 2012 Jun 15;1460:25-32
pubmed: 22595749
Biol Psychiatry. 2009 Apr 15;65(8):696-701
pubmed: 18990365
Eur J Pharmacol. 1986 Jul 31;126(3):223-9
pubmed: 2875886
Nat Rev Neurosci. 2011 Oct 12;12(11):623-37
pubmed: 21989194
J Neurosci. 2014 Mar 5;34(10):3467-74
pubmed: 24599448
J Neurosci. 2014 Jul 2;34(27):9076-87
pubmed: 24990928
Curr Top Behav Neurosci. 2016;28:53-91
pubmed: 27418067
J Neurosci. 2011 Nov 9;31(45):16447-57
pubmed: 22072694
Psychiatr Ann. 2008 Nov;38(11):724-729
pubmed: 20717489